President & Chief Executive Officer, Board Member

Chief Financial Officer

Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting

Clear Street Initiates Buy on Dianthus Therapeutics, Inc. (DNTH) With $100 Price Target

Dianthus initiated with bullish view at Clear Street, here's why

Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again

Senior Director, Regulatory Combination Product

Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing novel monoclonal antibodies for severe autoimmune and inflammatory diseases. The Senior Director, Regulatory Combination Product will define and drive regulatory compliance for biologics-device combination products, collaborating with cross-functional teams to support product development and commercialization.

Sign up with Google

Sign in with Google